Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Jupiter Neurosciences (JUNS) EBITDA (2024 - 2025)

Jupiter Neurosciences (JUNS) has disclosed EBITDA for 2 consecutive years, with -$2.8 million as the latest value for Q4 2025.

  • Quarterly EBITDA fell 92.6% to -$2.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$8.9 million through Dec 2025, down 189.27% year-over-year, with the annual reading at -$8.9 million for FY2025, 188.19% down from the prior year.
  • EBITDA for Q4 2025 was -$2.8 million at Jupiter Neurosciences, down from -$2.3 million in the prior quarter.
  • The five-year high for EBITDA was -$493547.0 in Q3 2024, with the low at -$2.8 million in Q4 2025.